NeuroSave, Inc. Secures $1

NeuroSave, Inc., a clinical-stage medical device company, has secured $100,000 in investment capital from investors.

This funding round will support the company's ongoing efforts to develop innovative solutions for preventing and treating ischemic brain injury.

NeuroSave is dedicated to addressing brain damage caused by surgery, cardiac arrest, stroke, or trauma through its unique therapeutic approach.

The company's core mission is to rapidly deliver the benefits of therapeutic hypothermia directly to the brain while simultaneously protecting the body from the negative effects of cooling.

NeuroSave achieves cerebral cooling by circulating cold fluid in the aerodigestive tract, which in turn cools the blood in the arteries traveling to the brain.

This method results in rapid brain-targeted cooling, a critical factor in mitigating brain injury.

NeuroSave's technology has demonstrated significant promise in both animal and human trials.

These studies showed cerebral cooling that is substantially faster than any currently available non-surgical approach, capable of creating a notable temperature difference between the body's core and the brain.

The newly raised capital is expected to be allocated towards advancing its clinical development programs and scaling its operational capabilities.

This investment underscores confidence in NeuroSave's potential to make a meaningful impact in neurocritical care.

The company plans to leverage these funds to accelerate its progress towards bringing its life-saving technology to patients, ultimately aiming to improve outcomes for individuals at risk of ischemic brain injury.